HealthRX
#11A LegitScript-certified, physician-supervised program with a rare oral GLP-1 tablet alongside injectables — both molecules, transparent no-insurance pricing, and a brand-name path.
- Sema
- $193/mo
- Tirz
- $242/mo
- Coverage
- All 50 states
Ranked by the Match Score
FuturHealth scores 61 on our six-factor Match Score (ranked #319 of 537). Here are the providers we'd weigh against it, ranked by that same honest model. Or take the quiz for your personalized match.
A LegitScript-certified, physician-supervised program with a rare oral GLP-1 tablet alongside injectables — both molecules, transparent no-insurance pricing, and a brand-name path.
He & She MD is a nationwide telehealth weight-loss clinic offering doctor-prescribed GLP-1 medications: compounded semaglutide and tirzepatide (injectable or oral), with brand-name…
The best all-around match: nationwide access, both molecules at one flat, no-surprise price, and an easy exit.
Weight-loss treatment from $199/mo across all 50 states plus Puerto Rico, spanning compounded injectables, oral tablets and brand-name Ozempic — but the price you actually pay appears only after intake.
The one brand-name-only option here: you pick a named clinician at a posted price, and the medication is billed separately at cash-pay rates.
One of the widest formularies in the ranking — both molecules, an oral route, and brand access, all nationwide.
A weight-focused program that also offers an oral/sublingual route for the needle-averse.
The highest Transparency score here, and it is not close: twenty-four prices on one public page and four dispensing pharmacies named with street addresses.
Answer six quick questions and we'll reweight the Match Score to your budget, format, timing, coverage and support — then rank every provider for you.
Take the quizPricing, states and verification reflect each provider's public disclosures at last review; the Match Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.